Literature DB >> 11145220

Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers.

E Liang1, J Proudfoot, M Yazdanian.   

Abstract

PURPOSE: To investigate the mechanisms involved in transport of sulfasalazine in Caco-2 cells.
METHODS: Permeability coefficients of sulfasalazine and its analogs across Caco-2 cell monolayers were measured as a function of direction of transport, energy and concentration dependence, and in the presence of inhibitors of various cellular efflux pumps and transporters.
RESULTS: Permeability coefficients of sulfasalazine across Caco-2 cell monolayers were approximately 342-, 261-, and 176-fold higher from basolateral to apical direction (BL-->AP) than from apical to basolateral direction (AP-->BL) at 100, 200, and 500 microM, respectively. Carrier permeability coefficient, non-saturable membrane permeability coefficient, and Michaelis constant were estimated to be 1.4x10(-5) cm/s, 1.9x10(-8) cm/s, and 369 microM, respectively. The efflux of sulfasalazine was completely blocked at 4 degrees C and in the presence of an uncoupler of oxidative phosphorylation. Using cellular efflux inhibitors, the permeability of sulfasalazine was shown to depend on multidrug resistance-associated protein and anion sensitive transport mechanisms. Structure-permeability studies showed that the affinity of sulfasalazine for the cellular efflux pumps and transporters in Caco-2 cells depended strongly on the carboxylic acid functional group.
CONCLUSIONS: The permeability of sulfasalazine across Caco-2 cell monolayer is very low due to its strong interaction with multiple cellular efflux pumps and transporters. This may partially explain its low absorption in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11145220     DOI: 10.1023/a:1026450326712

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  27 in total

1.  pH-dependent intestinal transport of monocarboxylic acids: carrier-mediated and H(+)-cotransport mechanism versus pH-partition hypothesis.

Authors:  A Tsuji; M T Simanjuntak; I Tamai; T Terasaki
Journal:  J Pharm Sci       Date:  1990-12       Impact factor: 3.534

2.  Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers.

Authors:  M Sudoh; G M Pauletti; W Yao; W Moser; A Yokoyama; A Pasternak; P A Sprengeler; A B Smith; R Hirschmann; R T Borchardt
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

3.  Transport characteristics of diphenhydramine in human intestinal epithelial Caco-2 cells: contribution of pH-dependent transport system.

Authors:  H Mizuuchi; T Katsura; H Saito; Y Hashimoto; K I Inui
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

4.  Basolateral Cl-/HCO3- exchange in rat jejunum: evidence from H14CO3- uptake in membrane vesicles.

Authors:  M N Orsenigo; M Tosco; A Faelli
Journal:  Biochim Biophys Acta       Date:  1992-07-27

Review 5.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

6.  Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.

Authors:  V D Makhey; A Guo; D A Norris; P Hu; J Yan; P J Sinko
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

7.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

8.  Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter.

Authors:  S Döppenschmitt; H Spahn-Langguth; C G Regårdh; P Langguth
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

9.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

10.  Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells.

Authors:  Z Holló; L Homolya; T Hegedüs; B Sarkadi
Journal:  FEBS Lett       Date:  1996-03-25       Impact factor: 4.124

View more
  14 in total

1.  The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs.

Authors:  Mehran Yazdanian; Katherine Briggs; Corinne Jankovsky; Amale Hawi
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

2.  Transport studies with 5-aminosalicylate.

Authors:  Hua-Wen Xin; Matthias Schwab; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2006-08-30       Impact factor: 2.953

3.  Predicting effect of food on extent of drug absorption based on physicochemical properties.

Authors:  Chong-Hui Gu; Hua Li; Jaquan Levons; Kimberley Lentz; Rajesh B Gandhi; Krishnaswamy Raghavan; Ronald L Smith
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

4.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 5.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 6.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 7.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Real-time imaging and quantitative analysis of doxorubicin transport in a perfusable microvessel platform.

Authors:  Max I Bogorad; Peter C Searson
Journal:  Integr Biol (Camb)       Date:  2016-08-15       Impact factor: 2.192

9.  Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha.

Authors:  J van der Heijden; M C de Jong; B A C Dijkmans; W F Lems; R Oerlemans; I Kathmann; C G Schalkwijk; G L Scheffer; R J Scheper; G Jansen
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

10.  A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP.

Authors:  Lei Zhang; Junfang Zhao; Chenmeizi Liang; Mingyao Liu; Feng Xu; Xin Wang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.